Insulet Corp (PODD)

41.94
NASDAQ : Health Care
Prev Close 41.60
Day Low/High 41.33 / 42.17
52 Wk Low/High 23.94 / 45.19
Avg Volume 570.90K
Exchange NASDAQ
Shares Outstanding 57.27M
Market Cap 2.38B
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Insider Bets Paying Off At PODD As New 52-Week High Reached

Insider Bets Paying Off At PODD As New 52-Week High Reached

In trading on Thursday, shares of Insulet Corp touched a new 52-week high of $43.48/share. That's a 81.62% rise, or $19.54 per share from the 52-week low of $23.94 set back on 02/12/2016.

Insulet Reports Second Quarter 2016 Financial Results

Insulet Reports Second Quarter 2016 Financial Results

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial results for...

Insulet Corporation To Present At Upcoming Investor Conferences

Insulet Corporation To Present At Upcoming Investor Conferences

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at three...

12 Year Old Podder™ Trent Wright Exploring Omnipod's New Toby's T1D Tale Educational App. (Photo: Business Wire)

12 Year Old Podder™ Trent Wright Exploring Omnipod's New Toby's T1D Tale Educational App. (Photo: Business Wire)

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced the introduction of...

Insulet Corporation To Announce Second Quarter 2016 Financial Results On August 3, 2016

Insulet Corporation To Announce Second Quarter 2016 Financial Results On August 3, 2016

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results...

New Data Demonstrate Benefits Of Insulet's Omnipod® System For People With Type 1 And Type 2 Diabetes

New Data Demonstrate Benefits Of Insulet's Omnipod® System For People With Type 1 And Type 2 Diabetes

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), today announced two online publications of new data in the Journal of...

Insulet Partners With Joslin Diabetes Center To Implement A Unique Training Certification For Insulet's Clinical Team

Insulet Partners With Joslin Diabetes Center To Implement A Unique Training Certification For Insulet's Clinical Team

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that almost 100 members of Insulet's...

Insulet To Present Omnipod® Clinical Studies On Type 1 And Type 2 Diabetes During The American Diabetes Association's 76th Scientific Sessions

Insulet To Present Omnipod® Clinical Studies On Type 1 And Type 2 Diabetes During The American Diabetes Association's 76th Scientific Sessions

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced new clinical data...

Insider Trading Alert - PODD, POWI And SNSS Traded By Insiders

Insider Trading Alert - PODD, POWI And SNSS Traded By Insiders

Stocks with insider trader activity include PODD, POWI and SNSS

Insulet Launches New Omnipod® Podder™ Community Platform

Insulet Launches New Omnipod® Podder™ Community Platform

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced the launch of a new...

Insulet (PODD) Is Strong On High Volume Today

Insulet (PODD) Is Strong On High Volume Today

Trade-Ideas LLC identified Insulet (PODD) as a strong on high relative volume candidate

On Tap for Analysts: Boston Scientific, Ford, Western Digital

On Tap for Analysts: Boston Scientific, Ford, Western Digital

Here are Friday's top research calls, including downgrades for Ford, Synaptics and Western Digital, and an upgrade for Boston Scientific.

Short Interest In Insulet Increases 15.2%

Short Interest In Insulet Increases 15.2%

The most recent short interest data has been released by the NASDAQ for the 03/15/2016 settlement date, which shows a 705,381 share increase in total short interest for Insulet Corp , to 5,359,798, an increase of 15.16% since 02/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Insulet Names Aiman Abdel-Malek, Ph.D. Senior Vice President Of Advanced Technology And Engineering

Insulet Names Aiman Abdel-Malek, Ph.D. Senior Vice President Of Advanced Technology And Engineering

Experienced Senior Executive with Proven Record Leading Global R&D Teams

Insider Trading Alert - PBCT, PODD And SPH Traded By Insiders

Insider Trading Alert - PBCT, PODD And SPH Traded By Insiders

Stocks with insider trader activity include PBCT, PODD and SPH

Insider Trading Alert - PODD, AME And LDL Traded By Insiders

Insider Trading Alert - PODD, AME And LDL Traded By Insiders

Stocks with insider trader activity include PODD, AME and LDL

Insulet Announces Organizational Enhancements

Insulet Announces Organizational Enhancements

Shacey Petrovic Promoted to President, Insulet Diabetes Products

Insulet Announces Development Partner For The OmniPod Artificial Pancreas

Insulet Announces Development Partner For The OmniPod Artificial Pancreas

Company's Alliance with Algorithm Partner Marks Critical Step Forward in Advanced Diabetes Treatment

Insulet Appoints David A. Lemoine To Board Of Directors

Insulet Appoints David A. Lemoine To Board Of Directors

New Independent Director Brings Extensive Accounting and Financial Reporting Expertise

Insulet To Divest Neighborhood Diabetes Supplies Business

Insulet To Divest Neighborhood Diabetes Supplies Business

Signs definitive agreement to sell Neighborhood Diabetes to Liberty Medical

Insulet Raises Funds For Continued Diabetes Research

Insulet Raises Funds For Continued Diabetes Research

Company Fund-Raising Program Results in a $10,000 donation each to the ADA and JDRF